Non-small cell lung cancer
RecruitingStudy of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response
Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+5
Spain- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Merck Sharp & Dohme LLC








